U.S. spending on biosimilars by type 2014
This statistic displays the annual spending on biosimilars in the United States in 2014, by type. During this year, 8.6 billion U.S. dollars that were spent on insulins were to expire between 2015 and 2019. In 2009, the Biologics Price Competition and Innovation Act established a biosimilar pathway which has led to several applications and approvals.
